Vicore Pharma Holding AB (publ)

DB:6Y4 Stock Report

Market Cap: €174.1m

Vicore Pharma Holding Valuation

Is 6Y4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6Y4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6Y4's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6Y4's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6Y4?

Other financial metrics that can be useful for relative valuation.

6Y4 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.5x
Enterprise Value/EBITDA-6.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 6Y4's PS Ratio compare to its peers?

The above table shows the PS ratio for 6Y4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.8x
2INV 2invest
7.7xn/a€59.8m
HPHA Heidelberg Pharma
15x19.1%€126.8m
FYB Formycon
15.2x32.5%€925.2m
BIO3 Biotest
1.4x-4.1%€1.4b
6Y4 Vicore Pharma Holding
18.9x-95.0%€2.0b

Price-To-Sales vs Peers: 6Y4 is expensive based on its Price-To-Sales Ratio (18.9x) compared to the peer average (9.8x).


Price to Earnings Ratio vs Industry

How does 6Y4's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 6Y4 is expensive based on its Price-To-Sales Ratio (18.9x) compared to the European Biotechs industry average (9.1x).


Price to Sales Ratio vs Fair Ratio

What is 6Y4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6Y4 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.9x
Fair PS Ratio0.08x

Price-To-Sales vs Fair Ratio: 6Y4 is expensive based on its Price-To-Sales Ratio (18.9x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6Y4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.69
€3.16
+356.7%
8.1%€3.52€2.81n/a4
Oct ’25€0.65
€3.20
+392.2%
9.1%€3.52€2.82n/a3
Sep ’25€1.37
€4.43
+224.3%
30.1%€6.14€2.81n/a4
Aug ’25€1.53
€5.33
+248.1%
31.0%€7.27€2.77n/a4
Jul ’25€1.85
€5.33
+187.5%
31.0%€7.27€2.77n/a4
Jun ’25€1.62
€5.33
+227.9%
31.0%€7.27€2.77n/a4
May ’25€1.51
€5.33
+253.1%
31.0%€7.27€2.77n/a4
Apr ’25€1.28
€5.33
+317.3%
31.0%€7.27€2.77n/a4
Mar ’25€1.22
€6.02
+394.4%
32.3%€8.51€2.81n/a5
Feb ’25€1.18
€5.96
+404.0%
34.4%€8.17€2.69n/a4
Jan ’25€1.28
€5.96
+365.4%
34.4%€8.17€2.69n/a4
Dec ’24€1.28
€5.96
+363.9%
34.4%€8.17€2.69n/a4
Nov ’24€1.08
€5.96
+452.6%
34.4%€8.17€2.69n/a4
Oct ’24€1.29
€5.96
+361.8%
34.4%€8.17€2.69€0.654
Sep ’24€1.30
€5.96
+359.6%
34.4%€8.17€2.69€1.374
Aug ’24€1.58
€5.98
+278.7%
34.4%€8.20€2.71€1.534
Jul ’24€1.48
€6.10
+313.0%
35.1%€8.39€2.68€1.854
Jun ’24€1.62
€6.44
+297.0%
31.0%€8.67€2.77€1.625
May ’24€1.69
€6.29
+271.9%
29.8%€8.71€2.78€1.516
Apr ’24€1.50
€6.29
+318.4%
29.8%€8.71€2.78€1.286
Mar ’24€1.24
€6.32
+409.8%
29.8%€8.76€2.80€1.226
Feb ’24€1.49
€6.67
+349.0%
31.2%€8.76€2.77€1.186
Jan ’24€1.60
€7.69
+381.0%
16.7%€9.03€5.53€1.285
Dec ’23€2.16
€7.69
+256.6%
16.7%€9.03€5.53€1.285
Nov ’23€2.70
€7.39
+174.2%
15.4%€8.91€5.51€1.085
Oct ’23€2.59
€7.47
+189.0%
15.4%€9.01€5.57€1.295

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies